Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2021-07-20
Target enrollment:
Participant gender:
Summary
The objective is to determine whether nebivolol, a beta-blockade drug, can prevent the
development of heart disease in patients with Duchenne muscular dystrophy aged 10 to 15
year-old.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Association Française contre les Myopathies (AFM), Paris